Study finds salicin show anti-colon cancer activity

Today's rapid development of malignant tumors, colon cancer incidence rate increased year by year, increasing the social and economic burden, is a serious threat to human healthTreatment of malignant tumors mainly includes surgical treatment, chemotherapy and radiotherapy, and according to statistics, about 60% of patients receive chemotherapyWith the improvement of the surgical method, the application of the combination of the therapeutic surgery and the comprehensive treatment of perioperative surgery has significantly extended the survival time of colorectal cancer patientsUnder the premise of the root-and-branch removal of the tumor, the importance of reducing the body's trauma and protecting organ function is increasing, at the same time, the long-established perioperative treatment plan is new, the new results show that shortening assisted chemotherapy to three months can reduce the occurrence of chemotherapy-related adverse events, without affecting the survival benefits of patients, moving some or all of the auxiliary treatment courses to the preoperative may improve the tumor response, and ultimately avoid surgery or radiotherapyIt can be seen the importance of chemotherapy, in recent years, the development of chemotherapy drugs has made many new progresssalimycin is a kind of antibiotic isolated from white streptomyces fermentation solution in 1974, which is widely used to prevent and control poultry ballworm disease, has long been used as veterinary medicine, but researchers first found in 2009 that salimycin can selectively kill breast cancer tumor stem cells, the effect is more than 100 times higher than commonly used breast cancer chemotherapy drug yewolsalimycin can be used to control tumor growth and diffusion by blocking the signaling pathways in tumor stem cells, inhibiting drug exoplanet pumps and cell autophagy, and regulating tumor microenvironmentSubsequent results showed that salimycin can effectively inhibit the proliferation of a variety of tumor cells such as ovarian cancer, nasopharyngeal cancer, oral cancer and lung cancer and promote its apoptosis, but the effect of salimycin on colon cancer is not clearIn June this year, researchers from Guangdong, China, and Shanghai Jiaotong University Biomedical Center jointly found that salimycin showed anti-colon cancer activity by acting on beta-cycline/T cytokine complex, but the specific mechanism of salicin's effect on colon cancer tumor stem cells remained unclearThe researchers further found that the results showed that salithromycin blocked beta-cycline/T cytokines in colon cancer cells and in vitro GST pull-down experiments, reducing the expression of the Wnt target geneSalimycin also inhibits the transcriptional activity of beta-cycline/T cytokine complex, showing inhibition of the internal environment, cell proliferation, and independent growth of colon cancer cellsIn fraconopensie transplanted mice with colon cancer, injection of salithromycin can significantly slow the growth of tumor cells and the expression of Wnt-related target gene LGR5study suggests that salimycin may be a chemotherapy drug for colon cancer, providing new options for chemotherapy drugs in patients with colon cancerMaximizing functionality, achieving a better quality of life and extending survival times has become the eternal theme and ultimate goal of evolving colorectal cancer treatmentAt present, there is no clinical drug for tumor treatment in the world, more research is still in the laboratory research and clinical trial stage, the existing U.SVerastem products (main component of salimycin) clinical Phase I, II clinical trials show that salithromycin can effectively control tumor metastasis, and clinical side effects are notreferences: 1.Wang Z, Zhou L, Xiong Y, et al Salinomycin exerts anti-color cancer activity by targeting the beta-catenin/T-cell factor complex Br J Pharmacol 2019,176(17):3390-3406 2 Advances in the treatment of thalimycin nanoagents in tumor stem cell therapy.Jiang Fan, Wei Xin Clinical Journal of Practical Hospital.2019,16 (2): 236-238.